You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tyrosine Kinase Inhibitor (TKI) Therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

CML (Chronic Myelogenous Leukemia Trial (KDS-1001)

Not yet recruiting
  • CML (Chronic Myelogenous Leukemia
  • (no location specified)
Jul 27, 2022

HRQOL in Locally Advanced Thyroid Carcinoma

Recruiting
  • Thyroid Cancer
  • +2 more
  • Tyrosine kinase inhibitor drugs.
  • Fuzhou, Fujian, China
    Road Fuma No.420
Apr 11, 2023

Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer Trial in Tampa (Lenvatinib, Sorafenib, Cabozantinib)

Terminated
Has Results
  • Thyroid Cancer
  • +5 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jul 12, 2021

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
May 23, 2023

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

NSCLC Trial in Seoul (BBT-176, Cetuximab)

Recruiting
  • NSCLC
  • Seongnam-si, Gyeonggi-do, Korea, Republic of
  • +3 more
Jan 6, 2023

Renal Cell Carcinoma Trial in Omaha, Cleveland, Philadelphia (Axitinib)

Terminated
Has Results
  • Renal Cell Carcinoma
  • Omaha, Nebraska
  • +2 more
Jul 26, 2021

NSCLC Trial in Seoul (SNK01 (Super Natural Killer Cells 01), GC, Cetuximab)

Recruiting
  • Non-small Cell Lung Cancer
  • SNK01 (Super Natural Killer Cells 01)
  • +2 more
  • Seoul, Songpa-gu, Korea, Republic of
    Asan Medical Center
Jul 15, 2021

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

Condition Vasoregulation Function Endothelium in CML Getting TKI

Recruiting
  • Chronic Myeloid Leukaemia
  • taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
  • Moscow, Russian Federation
  • +1 more
Jan 11, 2023

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult Trial in Xi'an

Recruiting
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • +2 more
  • Xi'an, Shaanxi, China
    First Affiliated Hospital of Xian Jiaotong University
Sep 29, 2021

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Rotterdam, Netherlands
      Erasmus MC
    Feb 2, 2022

    Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • Philadelphia Chromosome-Positive
    • Blinatumomab
    • +3 more
    • New York, New York
    • +1 more
    Nov 10, 2022

    Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia Trial in Philadelphia (Text

    Recruiting
    • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Chronic Phase Chronic Myelogenous Leukemia
    • Text Message-Based Navigation Intervention
    • Survey Administration
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Apr 7, 2022

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer Trial in Duarte (other, dietary supplement, drug)

    Active, not recruiting
    • Diarrhea
    • +2 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Jun 7, 2022

    Metabolic Alternation and Clinicohematological Characteristic in

    Not yet recruiting
    • CML, Chronic Phase
    • Tyrosine kinase inhibitor
    • (no location specified)
    Nov 6, 2023

    Stage IV Renal Cell Cancer AJCC V7 Trial in Calgary, Toronto (Pembrolizumab, Stereotactic Body Radiation Therapy)

    Completed
    • Stage IV Renal Cell Cancer AJCC V7
    • Calgary, Alberta, Canada
    • +2 more
    Aug 26, 2021

    Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)

    Not yet recruiting
    • Tyrosine Kinase Inhibitors
    • Chronic Myeloid Leukemia
    • treatment of TKI in CML
    • Poitiers, France
      Chu Poitiers
    Feb 21, 2023

    Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

    Recruiting
    • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
    • Topical Timolol
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Nov 14, 2023

    TKI Discontinuation in CML Patients of China

    Recruiting
    • Leukemia
    • +4 more
      • Shenzhen, Guangdong, China
        Shenzhen Second People's Hospital
      Mar 15, 2022

      Stage IV EGFR Mutated NSCLC Trial in Chengdu (Radiation: SBRT, TKI (Gefitinib or Tarceva ))

      Terminated
      • Stage IV EGFR Mutated Non-Small Cell Lung Cancer
      • Radiation: SBRT
      • TKI (Gefitinib or Tarceva )
      • Chengdu, Sichuan, China
        Sichuan PPH, Cancer Center
      Jan 29, 2021